Scholar Rock Holding Corporation
As of Oct 22, 2026, Scholar Rock Holding is in Stage 3, the topping phase, now in week 4 (since Sep 25, 2026). It closed at $41.96, 30.1% below its 52-week high and below its 200-day average, which is falling.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SRRK early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SRRK among Biotechnology90th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …90 | SRRK | Stage 3 · wk 4 | 86 | −15.8% |
Scholar Rock Holding: quick answers
What stage is Scholar Rock Holding in?
As of Oct 22, 2026, Scholar Rock Holding (SRRK) is in Stage 3, the topping phase. It entered Stage 3 on Sep 25, 2026 and is in week 4. What the four stages mean
Is Scholar Rock Holding in an uptrend?
Its uptrend has stalled. Scholar Rock Holding is in Stage 3, the topping phase that follows an advance. It trades 13.0% below its 200-day average, which is falling.
How far is Scholar Rock Holding from its 52-week high?
Scholar Rock Holding closed at $41.96 on Oct 22, 2026, 30.1% below its 52-week high of $60.04. Its 52-week low is $27.99.
How has Scholar Rock Holding performed over the past year?
As of Oct 22, 2026, Scholar Rock Holding is up 49.0% over the past year and down 2.0% so far in 2026.
Which sector and industry is Scholar Rock Holding in?
Scholar Rock Holding is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.